Ruffell Simon G D, Netzband Nige, Tsang WaiFung, Davies Merlin, Butler Matthew, Rucker James J H, Tófoli Luís Fernando, Dempster Emma Louise, Young Allan H, Morgan Celia J A
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London & South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, United Kingdom.
College of Life and Environmental Sciences, Washington Singer Laboratories, University of Exeter, Exeter, United Kingdom.
Front Psychiatry. 2021 Jun 9;12:687615. doi: 10.3389/fpsyt.2021.687615. eCollection 2021.
Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took part in ayahuasca ceremonies at a retreat centre in the Peruvian Amazon. Participants undertook the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Self-compassion Scale (SCS), Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM), as well as secondary measures, pre- and post-retreat and at 6-months. Participants also provided saliva samples for pre/post epigenetic analysis. Overall, a statistically significant decrease in BDI-II (13.9 vs. 6.1, < 0.001), STAI (44.4 vs. 34.3 < 0.001) scores, and CORE-OM scores were observed (37.3 vs. 22.3 < 0.001) at post-retreat, as well as a concurrent increase in SCS (3.1 vs. 3.6, < 0.001). Psychometric improvements were sustained, and on some measures values further decreased at 6-month follow-up, suggesting a potential for lasting therapeutic effects. Changes in memory valence were linked to the observed psychometric improvements. Epigenetic findings were equivocal, but indicated that further research in candidate genes, such as sigma non-opioid intracellular receptor 1 (SIGMAR1), is warranted. This data adds to the literature supporting ayahuasca's possible positive impact on mental health when conducted in a ceremonial context. Further investigation into clinical samples, as well as greater analyses into the mechanistic action of ayahuasca is advised.
阿亚瓦斯卡是一种天然的具有精神活性的药剂,用于亚马逊流域的传统仪式。最近的研究表明,阿亚瓦斯卡在药理上是安全的,其使用可能与精神症状的改善呈正相关。阿亚瓦斯卡的作用机制尚未完全明确。在这项前瞻性自然主义研究中,63名自行选择的参与者在秘鲁亚马逊地区的一个静修中心参加了阿亚瓦斯卡仪式。参与者在静修前后及6个月时进行了贝克抑郁量表(BDI-II)、状态-特质焦虑量表(STAI)、自我同情量表(SCS)、常规评估临床结果-结果测量量表(CORE-OM)以及一些次要测量。参与者还提供了唾液样本用于表观遗传学分析前/后的检测。总体而言,在静修后观察到BDI-II得分(1